Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
X4 Pharmaceuticals Inc's Business Segments
X4 Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 3
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 3 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Product91.2%
- License and Other Revenue8.8%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 2 | 91.2% |
| License and Other Revenue | $ 0 | 8.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of X4 Pharmaceuticals Inc
X4 Pharmaceuticals Inc. is a biopharmaceutical company based in the United States. It specializes in the discovery, development, and commercialization of novel therapies for the treatment of rare diseases and oncology indications. The company focuses on harnessing the power of the immune system and cell trafficking to develop innovative therapeutic approaches.
X4 Pharmaceuticals' main area of expertise lies in the development of small-molecule drugs that target the chemokine receptor CXCR4. CXCR4 is a receptor found on the surface of various cells in the body, including immune cells and cancer cells. The company's drug candidates are designed to selectively block the CXCR4 receptor, modulating immune responses and inhibiting cell migration, proliferation, and survival.
The company's lead drug candidate, mavorixafor, is being developed for multiple indications, including primary immunodeficiencies (PID), such as Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome, and clear cell renal cell carcinoma (ccRCC). Mavorixafor is intended to enhance the immune response by improving immune cell trafficking and function, ultimately leading to better disease outcomes.
In addition to mavorixafor, X4 Pharmaceuticals has a pipeline of other promising drug candidates targeting CXCR4. These candidates are at different stages of preclinical and clinical development, with the aim of addressing a range of diseases with unmet medical needs. The company employs a rigorous and iterative development process, leveraging a combination of in-house capabilities, collaborations with academic institutions, and strategic partnerships with other pharmaceutical companies.
To support its research and development efforts, X4 Pharmaceuticals has built a strong scientific and clinical team composed of experts in immunology, oncology, and drug development. The company also has collaborations with multiple leading academic institutions and research organizations to stay at the forefront of scientific advancements.
X4 Pharmaceuticals is committed to delivering innovative treatments to patients with rare diseases and oncology indications. It actively engages with patient advocacy groups, regulators, and other stakeholders to ensure patient voices are heard and incorporated into its drug development process. The company also recognizes the importance of commercialization and market access strategies to ensure its therapies reach the patients who need them.
Overall, X4 Pharmaceuticals Inc. is a biopharmaceutical company at the forefront of developing novel therapies that target the CXCR4 receptor. With a robust pipeline and a dedicated team, the company aims to make a meaningful impact on the lives of patients suffering from rare diseases and oncology indications.
X4 Pharmaceuticals' main area of expertise lies in the development of small-molecule drugs that target the chemokine receptor CXCR4. CXCR4 is a receptor found on the surface of various cells in the body, including immune cells and cancer cells. The company's drug candidates are designed to selectively block the CXCR4 receptor, modulating immune responses and inhibiting cell migration, proliferation, and survival.
The company's lead drug candidate, mavorixafor, is being developed for multiple indications, including primary immunodeficiencies (PID), such as Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome, and clear cell renal cell carcinoma (ccRCC). Mavorixafor is intended to enhance the immune response by improving immune cell trafficking and function, ultimately leading to better disease outcomes.
In addition to mavorixafor, X4 Pharmaceuticals has a pipeline of other promising drug candidates targeting CXCR4. These candidates are at different stages of preclinical and clinical development, with the aim of addressing a range of diseases with unmet medical needs. The company employs a rigorous and iterative development process, leveraging a combination of in-house capabilities, collaborations with academic institutions, and strategic partnerships with other pharmaceutical companies.
To support its research and development efforts, X4 Pharmaceuticals has built a strong scientific and clinical team composed of experts in immunology, oncology, and drug development. The company also has collaborations with multiple leading academic institutions and research organizations to stay at the forefront of scientific advancements.
X4 Pharmaceuticals is committed to delivering innovative treatments to patients with rare diseases and oncology indications. It actively engages with patient advocacy groups, regulators, and other stakeholders to ensure patient voices are heard and incorporated into its drug development process. The company also recognizes the importance of commercialization and market access strategies to ensure its therapies reach the patients who need them.
Overall, X4 Pharmaceuticals Inc. is a biopharmaceutical company at the forefront of developing novel therapies that target the CXCR4 receptor. With a robust pipeline and a dedicated team, the company aims to make a meaningful impact on the lives of patients suffering from rare diseases and oncology indications.
X4 Pharmaceuticals Inc. is a pioneering biotechnology firm dedicated to the discovery, development, and commercialization of advanced therapies, specifically tailored for rare diseases and immune-mediated disorders. The company leverages its expertise in the CXCR4 receptor pathway, a vital component implicated in a range of biological processes, to design therapies that address significant unmet medical needs.
Segments
X4 Pharmaceuticals is primarily positioned within the biopharmaceutical sector, and its operations can be classified into three major segments based on targeted therapeutic areas:
1. Rare Diseases:
- X4 Pharmaceuticals is committed to developing solutions for rare diseases that often lack effective treatment options. These conditions can present unique challenges due to their low prevalence and the specific needs of affected patients. By utilizing the CXCR4 pathway, the company aims to create therapies that can potentially enhance the quality of life for those with rare genetic disorders, immunodeficiencies, and other related conditions.
2. Oncology:
- In the oncology segment, X4 Pharmaceuticals is exploring how CXCR4-targeted therapies can play a significant role in cancer treatment. The CXCR4 receptor is known to be involved in tumor growth, metastasis, and the mechanisms by which cancer cells evade the immune system. The company is focused on developing agents that can inhibit these pathways to potentially halt cancer progression and improve survival rates for patients.
3. Immune-Mediated Disorders:
- The company also targets a spectrum of immune-mediated disorders, which occur when the immune system mistakenly attacks the body’s own tissues. Conditions like lupus, rheumatoid arthritis, and multiple sclerosis fall within this category. X4 Pharmaceuticals seeks to modulate the immune response via interventions on the CXCR4 pathway, with the aim of providing therapeutic relief and restoring balance to the immune system in affected individuals.
Products and Services
X4 Pharmaceuticals offers a diverse range of innovative products and services that target the CXCR4 pathway, which include the following:
1. X4P-001:
- Lead Product Candidate: X4P-001 is the flagship therapeutic agent under development for the treatment of WHIM syndrome, a rare inherited immunodeficiency disorder directly linked to genetic mutations in the CXCR4 receptor. This therapy is designed to improve immune cell trafficking, thereby enhancing immune responses in patients who experience severe complications due to this condition. Clinical trials are underway to evaluate its safety and effectiveness, with the goal of gaining regulatory approval.
2. Pipeline Products:
- Besides X4P-001, X4 Pharmaceuticals maintains a robust pipeline of various product candidates aimed at addressing multiple indications across the segments of rare diseases and oncology. These pipeline assets are at various stages of development, encompassing preclinical and clinical phases, and are specifically targeted at delivering novel treatment options that cater to patients with high unmet needs.
3. Research Collaboration:
- The company actively engages in collaborations with academic institutions, research organizations, and other pharmaceutical companies. These partnerships are pivotal for advancing the scientific understanding of the CXCR4 pathway, conducting innovative preclinical and clinical research, and facilitating joint discovery efforts. Collaborative projects can greatly enhance the prospects for uncovering new therapeutic approaches and expediting the development timeline for new interventions.
4. Clinical Trials and Regulatory Affairs:
- X4 Pharmaceuticals is heavily involved in the design and execution of clinical trials to validate the safety and efficacy of its product candidates. The company recognizes the importance of robust regulatory affairs strategies, ensuring adherence to relevant regulations and guidelines. This focus is critical for optimizing the pathways to product approval and commercialization, ultimately aiming to bring effective therapies to market in a timely manner.
Conclusion
X4 Pharmaceuticals stands at the forefront of biotechnology innovation, offering a comprehensive suite of products and services aimed at addressing the challenges posed by rare diseases, oncological conditions, and immune-mediated disorders. Through its relentless pursuit of research, collaborative ventures, and pipeline development, the company aspires to make a meaningful impact on patient outcomes, striving to enhance the lives of individuals affected by these complex medical conditions.
Segments
X4 Pharmaceuticals is primarily positioned within the biopharmaceutical sector, and its operations can be classified into three major segments based on targeted therapeutic areas:
1. Rare Diseases:
- X4 Pharmaceuticals is committed to developing solutions for rare diseases that often lack effective treatment options. These conditions can present unique challenges due to their low prevalence and the specific needs of affected patients. By utilizing the CXCR4 pathway, the company aims to create therapies that can potentially enhance the quality of life for those with rare genetic disorders, immunodeficiencies, and other related conditions.
2. Oncology:
- In the oncology segment, X4 Pharmaceuticals is exploring how CXCR4-targeted therapies can play a significant role in cancer treatment. The CXCR4 receptor is known to be involved in tumor growth, metastasis, and the mechanisms by which cancer cells evade the immune system. The company is focused on developing agents that can inhibit these pathways to potentially halt cancer progression and improve survival rates for patients.
3. Immune-Mediated Disorders:
- The company also targets a spectrum of immune-mediated disorders, which occur when the immune system mistakenly attacks the body’s own tissues. Conditions like lupus, rheumatoid arthritis, and multiple sclerosis fall within this category. X4 Pharmaceuticals seeks to modulate the immune response via interventions on the CXCR4 pathway, with the aim of providing therapeutic relief and restoring balance to the immune system in affected individuals.
Products and Services
X4 Pharmaceuticals offers a diverse range of innovative products and services that target the CXCR4 pathway, which include the following:
1. X4P-001:
- Lead Product Candidate: X4P-001 is the flagship therapeutic agent under development for the treatment of WHIM syndrome, a rare inherited immunodeficiency disorder directly linked to genetic mutations in the CXCR4 receptor. This therapy is designed to improve immune cell trafficking, thereby enhancing immune responses in patients who experience severe complications due to this condition. Clinical trials are underway to evaluate its safety and effectiveness, with the goal of gaining regulatory approval.
2. Pipeline Products:
- Besides X4P-001, X4 Pharmaceuticals maintains a robust pipeline of various product candidates aimed at addressing multiple indications across the segments of rare diseases and oncology. These pipeline assets are at various stages of development, encompassing preclinical and clinical phases, and are specifically targeted at delivering novel treatment options that cater to patients with high unmet needs.
3. Research Collaboration:
- The company actively engages in collaborations with academic institutions, research organizations, and other pharmaceutical companies. These partnerships are pivotal for advancing the scientific understanding of the CXCR4 pathway, conducting innovative preclinical and clinical research, and facilitating joint discovery efforts. Collaborative projects can greatly enhance the prospects for uncovering new therapeutic approaches and expediting the development timeline for new interventions.
4. Clinical Trials and Regulatory Affairs:
- X4 Pharmaceuticals is heavily involved in the design and execution of clinical trials to validate the safety and efficacy of its product candidates. The company recognizes the importance of robust regulatory affairs strategies, ensuring adherence to relevant regulations and guidelines. This focus is critical for optimizing the pathways to product approval and commercialization, ultimately aiming to bring effective therapies to market in a timely manner.
Conclusion
X4 Pharmaceuticals stands at the forefront of biotechnology innovation, offering a comprehensive suite of products and services aimed at addressing the challenges posed by rare diseases, oncological conditions, and immune-mediated disorders. Through its relentless pursuit of research, collaborative ventures, and pipeline development, the company aspires to make a meaningful impact on patient outcomes, striving to enhance the lives of individuals affected by these complex medical conditions.